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1. Introduction
As defined by the International Dry Eye Workshop, dry eye is a multifactorial disease of the
tears and ocular surface with symptoms of discomfort, visual disturbance, and tear film
instability with potential damage to the ocular surface resulting in a dysfunctional lacrimal
functional unit [1]. It is one of the most common medical problems that affects 6 to 44 million
people in the United States based on reported prevalence figures of 4 to 33% from large
epidemiological studies [2-4].
Dry eye affects quality of vision and quality of life. It is also associated with a significant
financial burden to the individual and society [5, 6]. It has been shown that dry eye significantly
decreases work productivity among office workers, by preventing them from performing at
their full potential [7]. The cost of work performance loss associated with dry eye was estimated
to be between $10-15 million/year in Japan [7].
The corneal surface irregularity in dry eye degrades visual function by decreasing contrast
sensitivity and functional visual acuity [8]. Visual impairment is one of the 10 most common
disabilities and vision impacts mobility, independence and quality of life. The presence of dry
eye was found to significantly impact the ability to perform daily activities such as reading,
using a computer and driving [9]. Visual impairments associated with dry eye disease have
been associated with falls and hip fractures in the elderly [10], and complications from these
falls is the leading cause of death from injury in men and women over the age of 65 [11]. As
vision deteriorates, one’s ability to perform activities of daily living becomes exceedingly more
difficult. Using time trade off techniques, Schiffman and colleagues calculated that patients
with severe dry eye expecting to live 10 years or more, were willing to give up 1.6 years of that
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time to be disease free [12], an amount similar to patients with moderate to severe angina [13].
Even though dry eye is a chronic disease, dry eye patients often complain about daily exacer‐
bations. One frequent complaint is worsening of irritation symptoms and vision after pro‐
longed use of a computer or grocery shopping.
While its pathogenesis has not been fully elucidated, it has been shown that changes in tear
composition including increased proinflammatory cytokines, chemokines, metalloproteinas‐
es, increased expression of immune activation and adhesion molecules by the conjunctival
epithelium and increased number of T lymphocytes in the conjunctiva play a pathogenic role
in both dry eye patients and in animal models [14-21]. Increased knowledge has shown that
inflammation is responsible in part for the irritation symptoms, ocular surface epithelial
disease including loss of goblet cell, conjunctival metaplasia, and altered corneal epithelial
barrier function in dry eye. This book chapter will discuss diverse pathogenic aspects of dry
eye.
2. Experimental animal models of dry eye
There are several  animal models of  dry eye currently used throughout the world.  They
have  been  used  to  evaluate  the  natural  history  of  the  disease,  to  elucidate  pathogenic
mechanisms (risk factors and molecular mediators, pathways) and also to evaluate efficacy
of therapeutic candidates. Models of dry eye rely on decreasing tear volume and produc‐
tion. To achieve that, surgical excision of the lacrimal gland, injection of pro-inflammato‐
ry cytokine IL-1 or isolated lymphocytes into the lacrimal gland, pharmacological blockade
of  lacrimal  gland secretion have been used [22-24].  Autoimmune strains have also been
studied. These strains have age-related lymphocytic infiltration of the lacrimal and salivary
glands and ocular surface inflammation mimicking Sjögren’s syndrome to a certain extent.
These include the non-obese diabetic  (NOD),  MRL/Lpr,  NZB/W F1 mouse,  and TGF-β1,
CD25 and Thrombospondin knock-out (KO) strains [25-32].
We have developed an inducible experimental murine dry eye model where wild-type mice
are subjected to an environmental stress for five or ten days and lacrimal gland secretion
is  pharmacologically  inhibited  by  administration  of  scopolamine.  Mice  are  kept  in  an
environmentally controlled room where relative humidity is kept below 30% at all times.
Mice subjected to this experimental model develop conjunctival goblet cell (GC) loss and
increased CD4+T cell infiltration in the conjunctival epithelium (Figure 1A) and increased
expression of inflammatory mediators, corneal barrier disruption measured by a fluores‐
cent dye (Figure 1B) similar to human dry eye patients (Figure 1C). Since the initial studies,
this experimental model has been used extensively by us and other groups within the US
but also worldwide. A significant body of evidence providing insight into the pathogene‐
sis  of  dry eye has been derived from this  animal model  and will  be discussed in more
detailed in the sequential topics.
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Figure 1. A. Representative images of immunohistochemical CD4+staining (red cells) in the goblet cell rich area of the
conjunctiva of C57BL/6 mice without desiccating stress (control, non-stressed, NS) and with desiccating stress for 5 or
10 days (DS5 or DS10, respectively). B. Representative images of Oregon-Green-Dextran corneal staining in C57BL/6
mice without desiccating stress (control, non-stressed “NS”) and with desiccating stress for 5 days (DS5). C. Represen‐
tative image of human cornea stained with sodium fluorescein and visualized under a blue filter showing punctate dry
spots in central cornea.
3. Role of tear hyperosmolarity
Hyperosmolarity has been shown to be a potent pro-inflammatory stimulus involved in the
pathogenesis  of  the  ocular  surface  disease  of  dry  eye,  termed keratoconjunctivitis  sicca
(KCS). Von Bahr was the first to suggest in 1941 that tear film osmolarity is dependent on
tear  secretion  and  evaporation,  and  that  decreased  secretion  would  lead  to  increased
osmolarity [33]. Balik appears to have been the first to suggest in 1952 that the corneal and
conjunctival changes in KCS could be explained on the basis of an increased "concentra‐
tion of sodium chloride" in the tear film [34]. It would not be until two decades later that
Mishima and colleagues were able to evaluate tear osmolarity and found an elevation of
about 25 mOsm/liter in six eyes with KCS [35]. Subsequent studies reported significantly
increased tear fluid osmolarity in patients with KCS, with the mean value 343 ± 32 (SD)
mOsM, and the ranging up to 441 mOsM [36]. Based on its sensitivity and specificity, tear
osmolarity was proposed as a gold standard diagnostic test for dry eye by Farris in 1992
[37], which was further evidenced by the fact that the use of sodium hyaluronate eye drops
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with  pronounced  hypotonicity  showed  greater  therapeutic  efficacy  on  the  severity  of
Sjögren's syndrome associated KCS than isotonic solutions [38].
In  rabbit  dry  eye  models,  the  elevated  tear  film  osmolarity  caused  decreased  corneal
glycogen and reduced conjunctival goblet cell density, as well as pathological changes in
the  corneal  epithelium,  such as  increased desquamation,  decreased intercellular  connec‐
tions,  blunting and loss  of  microplicae,  cell  membrane disruptions and cellular  swelling
[39-41]. In mice following 2 days of DS, tear volume significantly decreased from 0.066ul
to  0.026ul  in  C57BL/6J  and  0.093ul  to  0.028ul  in  BALB/c  mice  while  tear  osmolarity
concomitantly and significantly increased from 177 to 300 mOsM in C57BL/6J mice,  and
nearly doubled from 285 to 559 mOsM in BALB/C mice. Topical treatment of ocular surface
with hypertonic saline (500 mOsM) was found to stimulate expression and production of
interleukin (IL)-1β, tumor necrosis factor (TNF) α and MMP-9 by the corneal and conjunc‐
tival  epithelia,  when  compared  with  age  matched  controls  and  mice  treated  with  iso-
osmolar (305 mOsM) balanced salt solution [42, 43]. In our murine dry eye model [44], the
stimulated  expression  of  pro-inflammatory  mediator,  TNF-α,  IL-1β  and  MMP-9  was
observed [45]. The mitogen-activated protein kinases (MAPKs) are well conserved signal‐
ing pathways that include extracellular signal regulated kinases (ERK),  c-Jun N-terminal
kinases (JNK) and p38 MAPK [46-48]. Interestingly, the levels of phosphorylated JNK1/2,
ERK1/2,  and  p38  MAPKs  in  the  corneal  and  conjunctival  epithelia  were  markedly  in‐
creased in mice treated with hypertonic saline [45].
In human corneal epithelial cultures, the expression and production of a number of pro-
inflammatory  mediators,  IL-1β,  TNF-α,  IL-8,  and  MMPs,  including  gelatinase  MMP-9,
collagenases MMP-1 and MMP-13, and stromelysin MMP-3 were progressively increased
as the media osmolarity increased from 312 mOsM to 500 mOsM [49, 50]. Activated phospor
(p)-JNK-1/p-JNK-2 and p-ERK-1/p-ERK-2 were also detected by Western blot and peaked
at 60 minutes in cells exposed to hypertonic media. The levels of p-JNK-1/p-JNK-2 and p-
ERK1/p-ERK2 were positively correlated with the medium osmolarity. The inhibitors for
JNK or ERK pathways, SB202190, PD98059 and doxycycline markedly suppressed the levels
of phosphor-JNKs and/or ERKs, as well as these proinflammatory markers. Other investiga‐
tors  also  showed  that  hyperosmolarity  induced  the  pro-inflammatory  cytokine  and
chemokines  IL-6,  IL-8  and  monocyte  chemotactic  protein-1  in  cultured  human  corneal
epithelial cells [51]. The efficacy of doxycycline in treating ocular surface diseases may be
due to its ability to suppress JNK and ERK signaling activation and inflammatory media‐
tor production in the corneal epithelium.
Another  hallmark  of  dry  eye  is  cornea  and  conjunctiva  metaplasia,  where  the  normal
epithelium undergoes terminal differentiation and becomes keratinized [52]. The cornea is
a highly transparent tissue and this  abnormal keratinization process can lead to corneal
irregularity and blurred vision [53, 54]. In mice, we observed that desiccating stress induces
expression  of  cornified  envelope  proteins,  including  involucrin  and  small  proline-rich
proteins 2a and 2b in both cornea and conjunctiva [21, 55]. We also observed that stress-
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associated  pathway,  such  as  JNK,  ERK  and  p38  MAPK  are  activated  in  hours  after
desiccating stress starts [21, 43, 45].
We found increased levels of active phosphorylated JNK1 and JNK2 (JNK2 JNK1) in ocular
surface  epithelia  treated  with  hypertonic  saline  in  vivo  and in  cultured  human corneal
epithelial cells exposed to hyperosmolar media [45, 49, 56].  In vivo, we showed that the
JNK2 protein but not JNK1, appears to have an essential role in desiccation-induced corneal
epithelial  disease  by  stimulating production of  MMP-1,  MMP-9,  and cornified envelope
precursors as JNK2KO mice were resistant to dry eye-induced changes [20].
4. Role of matrix metalloproteinases
The hallmark  of  dry  eye  disease  is  the  increased  permeability  of  corneal  epithelium to
fluorescent dyes, clinically observed as fluorescent punctate spots. Because epithelial corneal
disease is responsible for the irritation and blurred vision symptoms reported by most dry
eye patients, corneal epithelium health is very important. The epithelium is not bystand‐
er,  but  actively  responds  to  desiccating  stress  by  secreting  inflammatory  cytokines,
chemokimes and matrix metalloproteinases (MMPs).
Matrix degrading enzymes including MMPs have been identified as important factors in
the inflammatory and wound healing response of the ocular surface, particularly in dry eye
and  ocular  burns.  Their  induction  during  wound  healing  is  thought  to  play  a  role  in
extracellular matrix remodeling,  cytokine activation,  and regulation of angiogenesis [57].
The MMP family includes more than 25 members that can be divided into collagenases that
degrade  fibrillar  collagen  types  I,  II,  and  III  (MMP-1,  -8,  -13);  gelatinases  that  degrade
collagen types IV, V, and VII and X as well as decorin, fibronectin, and laminin, that are
found in basement membranes (MMP-2,-9); stromelysins (MMP-3, and -10); matrilysins that
degrade proteoglycans, laminin, and glycoproteins (MMP-7 and -26); and the membrane-
type MMPs that are bound to epithelial cell membranes, and can activate MMPs, accord‐
ing to their structure and substrate specificity (MMPs 14-17, and -24) [58-61]. Collectively
they are able to degrade the entire extracellular matrix and basement membranes compo‐
nents. Barely detected in an unwounded cornea, MMPs are strongly induced during wound
healing. Among these, MMP–9 plays a prominent role being produced by stressed cornea
and  conjunctival  epithelial  cells  and  has  both  matrix  degrading  and  pro-inflammatory
activities [62-64].
Several members of MMPs have been found to increase in the corneal epithelium after
experimental dry eye and MMP-9 (Figure 2) [57]. MMP-9 has been found in tear fluid of dry
eye patients [65]. Of special interest, we have shown that epithelium-secreted MMP-9 after
experimental dry eye activates TGF-β [66], breaks-down the apical corneal epithelial tight
junctions (Figure 3), facilitating corneal barrier dysfunction [21, 57, 67] and accelerating corneal
desquamation [68].
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Figure 2. Laser scanning confocal microscopy of wholemount murine corneas stained for MMP-9 (in green) with pro‐
pidium iodide nuclear counterstaining (PI, in red), organized into non-stressed (NS) and desiccating stress for 5 days
(DS5).
MMP-9 knock-out mice are resistant to these changes, but exogenous topical administra‐
tion of MMP-9 to MMP-9KO mice induced increased corneal permeability in similar range
to wild-type control mice. Moreover, cultured human corneal epithelial cells treated with
MMP-9 showed breakdown of tight junction proteins, notably occludin [67]. In human dry
eye  patients,  increased  MMP-9  mRNA  transcripts  in  conjunctiva  and  increased  MMP-9
activity in tears was noted compared to normal subjects; increased MMP-9 activity in tears
positively correlated with symptom score,  cornea and conjunctiva staining,  low contrast
visual acuity and inversely correlated with tear-break-up [54]. In a group of dry eye patients,
we observed that tear MMP-9 activity levels increased as the severity of corneal disease
progressed (Table 1) [54].
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Figure 3. Laser scanning confocal microscopy of wholemount murine corneas stained for zona occludens 1 (ZO-1, in
green) with propidium iodide nuclear counterstaining (PI, in red), organized into non-stressed (NS) and desiccating
stress for 5 days (DS5). The NS controls show uniform cell with membrane staining while the DS5 corneas have in‐
creased apical cell loss (asterisk) and increase desquamation (arrows show either broken ZO-1 or cells that are rolling
up).
Group MMP-9 Activity (ng/mL)
Normal (n=18) 8.39 ± 4.70
Dysfunctional tear syndrome 1 (n=10) 62.40 ± 49.33**
Dysfunctional tear syndrome 2 (n=20) 58.84 ± 49.46**
Dysfunctional tear syndrome 3 (n=07) 116.99 ± 138.18**
Dysfunctional tear syndrome 4 (n=11) 360.25 ± 168.83**♦♦
Note: DTS=dysfunctional tear syndrome ** P<0.004 versus normal;♦♦P <0.007 versus normal and the other severity
based DTS groups
Table 1. Tear MMP-9 activity levels among normal subjects and dry eye patients stratified by 4 levels of severity
according to the Delphi Panel [69] [range from DTS1 (very mild) to DTS4 (severe dry eye)]
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5. The conjunctiva acts as an exogenous lymphoid tissue
Similar to other mucosal tissues, the conjunctiva is covered with epithelium containing
dendritic antigen presenting cells and a variety of intraepithelial lymphocyte (IEL) popula‐
tions, lymphocytes that reside outside the lymphoid organs and in contact with epithelial cells
in the gut, skin and lungs [70]. To date, several subsets of IELs have been identified in the
mouse and human conjunctiva, including CD4+, CD8+, gammadelta (γδ)+and NK+ cells[71-74].
The CD103 integrin has been used as a marker for IEL in different mucosal sites because it
mediates homing and retention of lymphocytes to the epithelium. Its ligand, E-cadherin is
highly expressed on mucosal epithelial cells [75, 76].
An important breakthrough in recent studies is the discovery of a link between the ocular
surface epithelium and immune cells. Soluble factors from immune cells have been found to
be either pathogenic or homeostatic to cornea and conjunctiva epithelium. Early biopsies from
Sjögren’s Syndrome (SS) patients have shown lymphocytic infiltration in the lacrimal gland
and activated T cells have been detected in the conjunctiva dry eye patients [77-82]. Animal
studies using the adoptive transfer experiment showed that dry eye can be induced in T cell
deficient nude mice that had never been exposed to desiccated stress by adoptively transferring
CD4+T cells from dry eye mouse model [83]. This landmark study showed that immunocom‐
petent recipients will only develop disease when regulatory cells are depleted with antibody
to CD25 [83]. Taken together, these experiments showed that: 1) dry eye is indeed an autoim‐
mune disease, since goblet cell loss and CD4+T infiltration was seen in naïve mice receiving
cells but never subjected to DS; 2) confirmed the pathogenic role of CD4+T cells as adoptive
transfer of unfractionated or non-CD4+T cells had minimal effect; 3) showed that CD4+T cells
primed in vivo during DS will migrate back to ocular surface tissues and LG; 4) dry eye induces
a systemic immune response, as adoptive transfer of splenic CD4+T cells was sufficient to
induce disease and 5) provided a mechanism to evaluate different components of the immune
system.
T helper (Th) CD4+T cells have been classically divided into Th-1, Th-2 and Th-17. Th-1
responses are important for controlling viral, fungal and intracellular bacterial infections. Th-1
cells are classically identified by the production of interferon-gamma (IFN-γ). Once commit‐
ted, the Th-1 cells activate macrophages and induce IgG2a production by B cells. Th-2
responses are frequently found in allergic diseases, such as asthma, and are particularly
important in the host response to parasites and helminthes in the gut. Th-2 cell differentiation
is promoted by interleukin (IL)-4 and it is characterized by production of IL-4, IL-13 and IL-5.
The Th-2 committed cells promote IgG1 and IgE class switching and eosinophil recruitment.
Th-17 cells are important in responding to extracellular bacterial and fungal pathogens, by
recruiting neutrophils and macrophages to infected tissues and have been implicated in
autoimmunity [84-86].
Migration of CD4+T cells into the conjunctival and cornea in dry eye disease may be modulated
by chemokine ligands produced by the surface epithelium that increase in dryness. Pathogenic
CD4 cells that infiltrate the ocular surface tissues express receptors to these ligands [18, 87, 88].
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5.1. Th-1 CD4+T cells in dry eye
Th-1 committed CD4+T cells secrete IFN-γ. CXCL9, CXCL10, CXCL11, IFN-γ inducible
chemokines, are highly expressed after experimental desiccating stress in both cornea and
conjunctiva [87-89] which will in turn attract more Th-1 cells, serving as an amplifying
mechanism.
IFN-γ has been proposed as a biomarker for dry eye disease and SS because elevated IFN-
γ,  either protein or RNA levels,  has been detected in tears [90-97],  conjunctiva [96-100],
saliva [101, 102], lacrimal [26, 103-108], submandibular glands [94, 103, 109-111], and blood
[112, 113].
Increased IFN-γ concentration in tears of dry eye patients detected by ELISA was reported
more than a decade ago. More sensitive immunoassays, such as Luminex and antibody
microarrays used in subsequent studies have confirmed these early results [90, 92-96]. In
addition to dry eye, increased tear IFN-γ concentration has also been found in patients with
sicca symptoms after bone marrow transplantation [90] and in tears of SS patients [91, 93].
Among the various subsets of dysfunctional tear syndrome, those with meibomian gland
disease (MGD) had significantly lower IFN-γ concentration than those without MGD [91, 92]
and tear IFN-γ concentration was found to correlate with corneal fluorescein staining score
[91]. It is possible that inflamed lacrimal glands in patients with SS are one source for their
increased tear IFN-γ.
Similarly  to  tears  [90],  increased IFN-γ has  been  found in  saliva  of  SS  patients  and its
presence correlated with sicca symptoms [101]. Interestingly, increased Th1/Th2 ratios was
observed in more severe SS cases [114-116], where increased Th-2 response correlated with
milder SS [101, 102, 117, 118]. Virtually every mouse autoimmune model that mimics SS or
even environmentally-induced mouse dry eye models have shown increased expression of
IFN-γ in LG and submandibular gland [26,  103-109,  118].  Increased expression of IFN-γ
mRNA  has  also  been  observed  in  the  conjunctiva,  both  in  dry  eye  patients  and  mice
subjected to dry eye [18, 96-100]. We have shown that IFN-γ induces conjunctiva metapla‐
sia  and apoptosis  and loss  of  conjunctival  goblet  cells  [97,  119,  120].  IFN-γKO mice are
resistant to dry eye induced changes but reconstitution of KO mice with exogenous IFN-γ
induces  goblet  cell  loss  in  similar  magnitude as  wild-type mice  and this  was  accompa‐
nied by cornification and apoptosis of conjunctival epithelium [97, 120].  It  has also been
shown  that  IFN-γ  significantly  decreases  epithelial  mucin  expression  [121].  Adoptive
transfer of CD4+T cells from donor mice exposed to desiccating stress that received anti-
IFN-γ  were  less  pathogenic  to  immunodeficient  mice  recipients,  yielding  less  corneal
apoptosis and greater number of PAS+filled goblet cells [119]. Mice that received subcon‐
junctival  injections  of  anti-IFN-γ  antibody  showed  decreased  corneal  and  conjunctival
apoptosis [98, 119].
5.2. Th-17 and NK cells in dry eye
IL-17A is the signature cytokine of the new discovered Th subtype, Th-17. The differentiation
of Th17 cells from naïve CD4+T cells is regulated by cytokines [122]. Transforming growth
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factor-β (TGF-β) and IL-6, broadly expressed by many cell types in the body, including
dendritic and epithelial cells, are dominant in the initiation of Th17 cell differentiation
[122-124]. IL-23, IL-1β and IL-21, which are products of activated dendritic cells, macrophages,
activated T cell or inflamed epithelial cells, possibly expand and maintain the differentiated
Th17 cells in the presence of IL-6 and TGF-β1 [122, 125, 126]. Furthermore, signal transducer
and activator of transcription 3 (STAT3) has been found to mediate the initiation of Th17 cell
differentiation by these inducing cytokines [127].
TGF-β is a critical factor in Th-17 differentiation. TGF-β is a pleiotropic cytokine that can have
pro- or anti-inflammatory effects depending on the context. It regulates various biologic
processes such as embryonic development, cell proliferation and differentiation, extracellular
matrix synthesis, immune response, inflammation, and apoptosis [128]. TGF-β1 is produced
by the human lacrimal gland (LG) and corneal and conjunctiva epithelia and has been detected
in tears [129, 130]. Elevated levels of bioactive TGF-β1 in tears and elevated TGF-β1 mRNA
transcripts in conjunctiva and minor salivary glands of human Sjögren’s Syndrome (SS)
patients has also been reported [18, 78, 131, 132].
We addressed the role of TGF-β in the Th-17 response in the conjunctiva by evaluating TGF-
β dominant-negative TGF-β type II receptor (CD4-DNTGFβRII) mice. These mice have a
truncated TGF-β receptor in CD4+T cells, rendering them unresponsive to TGF-β. These mice
exhibit an age-related dry eye phenotype at 14 weeks of age; however, when subjected to
desiccating stress, we observed that DS improved their corneal barrier function and corneal
surface irregularity, increased their number of PAS+GC, and lowered CD4+T cell infiltration
in conjunctiva. In contrast to WT, CD4-DNTGFβRII mice did not generate a Th-17 and Th-1
response, and they failed to upregulate MMP-9, IL-23, IL-17A, RORγT, IFN-γ and T-bet mRNA
transcripts in conjunctiva. RAG1KO recipients of adoptively transferred CD4+T cells isolated
from DS5 CD4-DNTGFβRII showed milder dry eye phenotype and less conjunctival inflam‐
mation than recipients of WT control [19].
Thrombospondin-1 (TSP-1) is an extracellular matrix protein that activates TGF-β1. When
covalently bound to TGF-β1, the latency associated peptide (LAP) blocks its active site and
renders the molecule inactive. This immature form of TGF-β1 naturally equilibrates with its
active state via detachment from LAP. Thrombospondin-1 stabilizes the covalent binding sites
on the disassociated LAP, thereby preventing its interaction and subsequent inhibition of TGF-
β1 [133]. As a result, increased levels of TSP-1 in the presence of TGF-β1 are linked to greater
levels of active TGF-β1 [133, 134]. Interestingly, similar to our findings in the CD4-DNTGFβRII
mice, TSP-1KO mice had decreased corneal surface dye staining, increased number of
conjunctival goblet cells and low levels of inflammatory cytokine mRNA transcripts in cornea
tissue compared to WT mice. We also showed that adoptive transfer of WT bone-marrow DC
into TSP-1KO reverted the TSP-1KO resistance to desiccating stress, showing that DC-derived
TSP is critical for the immune dry eye phenotype [135].
The corneal epithelium responds quickly to different stressors. Cultured human corneal
epithelial cells challenged by hyperosmotic media (450 mOsM), microbial components
(polyI:C, flagellin, R837, and other TLR ligands) and TNF-alpha responded by significantly
increasing expression of IL-6, TGF-β and IL-1β and IL-23 mRNA transcripts. Interestingly,
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when incubated with conditioned media of HCECs irritated by polyI:C or TNF-α, CD4+ T cells
displayed increased mRNA levels of IL-17A, IL-17F, IL-22, CCL-20, and STAT3, increased IL-17
protein in the supernatant, and increased numbers of IL-17-producing T cells (Th17 cells).
These findings demonstrate for the first time that Th17 differentiation can be promoted by
cytokines produced by corneal epithelium that are exposed to hyperosmotic, microbial, and
inflammatory stimuli [136].
Th17 cells can be identified by expression of CCR6 surface receptors [137-139]. CCR6 only
ligand known, CCL20, is highly expressed after injuries to epithelium, including experimental
desiccating stress [18]. Dry eye has been demonstrated to cause inflammation on the ocular
surface, evidenced by increased levels of inflammatory cytokines (IL-1, IL-6, IL-17 and TNF-
α) in the tear fluid and corneal and conjunctival epithelium, and an increased infiltration of
DCs and T lymphocytes in the conjunctiva [18, 79, 83, 96, 136, 140-144]. Increased levels of
IL-17, IL-23 and IL-6 were also found in saliva and salivary glands biopsies obtained from
patients with the severe autoimmune dry eye condition, Sjögren’s syndrome [145-147].
Evidence in mouse models of dry eye indicates that IL-17 stimulates production of MMP-3 and
MMP-9 that contribute to disruption of corneal epithelial barrier function. Recent studies have
shown that antibody neutralization of IL-17 ameliorated corneal barrier disruption in mice
subjected to desiccating stress [18, 148] and decreased expression of MMP-3 and-9 mRNA
transcripts in the corneal epithelium [18], providing a definitive link between epithelial and
immune cells in this process.
5.3. Goblet Cells in dry eye
The conjunctival epithelium is part of the few tissues in the body where goblet cells are present,
including the gut and the airway epithelia. Goblet cell loss is another clinical characteristic of
ocular surface diseases, including dry eye, Stevens-Johnson and ocular graft-versus-host-
diseases [149, 150]. Both NK and NKT cells are resident cells in conjunctiva [142]. NK cells are
a subtype of lymphocytes that lack expression of the antigen receptors expressed by B and T
cells; their name is derived from their ability to recognize and kill malignant cells. NKT cells
are defined as NK cells that express conventional T cell receptor (TCR). Both cell types are
important source of inflammatory cytokines, notably after encountering pathogens (viruses,
bacteria and protozoans). NKT cells have been involved in mucosal immunity and in a variety
of inflammatory/autoimmune diseases, such as experimental murine and human ulcerative
colitis, asthma, multiple sclerosis and skin diseases (atopic dermatitis, psoriasis) [151-153].
Using isolation techniques, we identified that NKT-derived IL-13 is trophic factor for con‐
junctival goblet cells, as IL-13KO and STAT6KO strains had lower goblet cell density than their
wild-type control mice [154]. In experimental murine dry eye, IL-13 significantly decreased in
tears after 5 and 10 days in Th-1 prone C57BL/6 mice, while it increased in BALB/C mice that
have been found to develop less severe corneal and conjunctival disease in response to
desiccating stress [96].
NK cells participate in the initiation of the immune response by releasing IFN-γ [99] and IL-17A
and by decreasing dendritic cell activation [142]. NK cells have been implicated in both the
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regulation and immunopathogenesis of dry eye disease since they are an early source of IFN-
γ during the induction phase of experimental dry eye disease [99]. Systemic depletion of NK
cells prior and during DS led to a decrease in the frequency of total and activated DCs, a
decrease in T helper-17(+) cells in the cervical lymph nodes and generation of less pathogenic
CD4+T cells. B6.nude recipient mice of adoptively transferred CD4+T cells isolated from NK-
depleted DS5 donor mice showed significantly less corneal barrier disruption, lower levels of
IL-17A, CCL20 and MMP-3 in the cornea epithelia compared to recipients of control CD4+T
cells [142].
5.4. Regulatory T Cells in dry eye
Resident CD8+T cells have been found in the epithelium and stroma of normal human and
mouse conjunctiva [97, 155], but their function remains unknown. In non-ocular tissues,
CD8+T cells have been found to have an immunoregulatory function. In the Lewis rat,
peripheral tolerance to orally administered antigens was mediated by TGF-β secreting CD8+T
cells [156, 157]. In the iris, CD8+T cells once activated in the presence of parenchymal cells,
expressed and secreted enhanced amounts of TGF-β2 [158]. In certain conjunctival inflamma‐
tory conditions, including graft-versus-host disease, Sjögren’s syndrome and human and
experimental murine keratoconjunctivitis, a significant decrease in CD8+T cells with concom‐
itant increase in CD4/CD8 ratio in the conjunctiva has been observed [74, 97, 159].
We have identified that CD8+ T cells can also function as regulatory cells. CD8+ T cell depletion
promoted generation of IL-17A producing CD4+T cells via activation of dendritic cells in both
the ocular surface and draining cervical lymph nodes in C57BL/6 mice subjected to DS. T cell-
deficient nude recipient mice receiving adoptively transferred CD4+T cells from CD8+cell-
depleted donors exposed to DS displayed increased CD4+T cell infiltration and elevated IL-17A
and CCL20 levels in the ocular surface, which was associated with greater corneal barrier
disruption. Enhanced DS-specific corneal barrier disruption in CD8-depleted donor mice
correlated with a Th17-mediated expression of MMP-3 and 9 in the recipient corneal epithe‐
lium. Co-transfer of CD8+CD103+Tregs did not affect the ability of DS-specific pathogenic
CD4+T cells to infiltrate and cause ocular surface disease in the nude recipients, showing that
CD8+cells regulate the afferent arm of DS-induced immune response. In summary,
CD8+regulatory cells suppress generation of a pathogenic Th17 response that plays a pivotal
role in DS-induced disruption of corneal barrier function [160].
6. Therapeutic strategies: from bench side to clinic
Traditionally, dry eye was treated with palliative solutions and frequent instillation of artificial
tears. With the change of paradigm and recognition of the role of inflammation in the disease,
several other modalities of treatment entered the pipeline. Animal models have suggested
potential agents/pathways.
Anti-protease therapy is very effective in treating dry eye associated corneal epithelial disease.
Previously reported studies using our experimental dry eye model demonstrated that the
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MMP inhibitor doxycycline and the steroid methylprednisolone was efficacious in decreasing
gelatinolytic activity and levels of MMP-9 transcripts in corneal epithelium, as well as
preventing the dry eye-induced increase in inflammatory cytokines IL-1 and TNF-α [161].
Doxycycline also improved corneal surface regularity and improved corneal barrier function
[21]. At the cellular level, doxycycline preserved apical epithelial cell area and the tight-
junction protein occludin, resulting in a decreased number of desquamating epithelial cells
from the surface of the cornea [21, 68]. The inhibitory effect of doxycycline on MMP-9 was also
confirmed on osmotically stressed cultured human corneal epithelial cells [67]. While there is
no FDA approved anti-inflammatory agents, both steroid and doxycycline eyedrops have also
been used with success in human dry eye patients [162, 163].
It has also been shown that manipulation of afferent (migration of DC into the regional lymph
nodes) or efferent (migration of differentiated cells from the nodes and into the cornea and
conjunctiva) can ameliorate development of dry eye disease [137, 164-167] indicating that
therapeutic strategies that interfere with various points in this immune circle may have clinical
significance.
Cyclosporine A 0.01 % emulsion (CsA), the only FDA-approved drug to treat dry-eye disease
has been shown to modulate several arms of the immune response by decreasing HLA-DR
expression in conjunctiva of dry eye patients [16, 168, 169] and decreasing expression of IL-17A
and IFN-γ in conjunctiva of animals after desiccating stress [18]. One beneficial side effect from
Cyclosporine emulsion is its significant effect increasing the amount of goblet cells in human
patients. We observed similar findings in our animal model as well: CsA topical treatment
prevented goblet cell loss, maintained the number of NK+cells in the conjunctiva increased
IL-13 mRNA in NK+cells, and decreased IFN-γ and IL-17A mRNA transcripts in NK+and NK-
populations, showing that CsA can act in both epithelial and immune compartments [154].
Novel therapeutic strategies based on the interruption of migration of Th17+CCR6+cells to the
ocular surface or production of IL-17 have been shown to ameliorated dry eye disease in animal
models of dry eye [18, 137, 142, 148, 165]. Exogenous administration of IL-13 to wild-type mice
subjected to desiccating stress for 5 days prevented DS-induced goblet cell loss [154]. Recently,
it has been made clear that strategies to neutralize IFN-γ may inhibit development of corneal
and conjunctival disease in experimental dry eye. Neutralization of NK cells, early producers
of IFN-γ (NK cells) following desiccating stress was found to decrease corneal fluorescein
staining and inflammatory cytokine expression in the cornea and conjunctiva [99, 142] and
also to decrease the Th-17 response.
7. Conclusions
This book chapter described the most recent advances in understanding the pathogenesis of
dry eye disease. A significant amount of work has been performed using an environmentally-
induced murine dry eye model. Inflammation is now recognized as important player in dry
eye. While there is just one FDA-approved drug to treat dry eye, several other drugs are in the
pipeline addressing different aspects of the disease and are potential new therapeutics.
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